WAC 246-945-350  Collaborative drug therapy agreements. (1) A pharmacist exercising prescriptive authority in their practice must have a valid CDTA on file with the commission and their practice location.

(2) A CDTA must include:
   (a) A statement identifying the practitioner authorized to prescribe and the name of each pharmacist who is party to the agreement;
      (i) The practitioner authorized to prescribe must be in active practice; and
      (ii) The authority granted must be within the scope of the practitioners' current practice.
   (b) A statement of the type of prescriptive authority decisions which the pharmacist is authorized to make, which includes:
      (i) A statement of the types of diseases, drugs, or drug categories involved, and the type of prescriptive authority activity (e.g., modification or initiation of drug therapy) authorized in each case.
      (ii) A general statement of the training required, procedures, decision criteria, or plan the pharmacist is to follow when making therapeutic decisions, particularly when modification or initiation of drug therapy is involved.
   (c) A statement of the activities the pharmacist is to follow in the course of exercising prescriptive authority, including:
      (i) Documentation of decisions made; and
      (ii) A plan for communication or feedback to the authorizing practitioner concerning specific decisions made.

(3) A CDTA is only valid for two years from the date of signing.

(4) Any modification of the written guideline or protocol shall be treated as a new CDTA.

[Statutory Authority: RCW 18.64.005, 18.64.080, 18.130.075, 18.64.043, 18.64.044, 18.64.045, 18.64.046, 18.64.370, 18.64.460, 69.50.310, 18.64.011, 18.64.245, 18.64.470, 18.64.255, 18.64.205, 18.64.253, 18.64.410, 18.64.500, 18.64.590. WSR 20-12-072, § 246-945-350, filed 6/1/20, effective 7/1/20.]